Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. The company is headquartered in Philadelphia, Pennsylvania and currently employs 161 full-time employees. The company went IPO on 2019-10-25. The firm is focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). CABA-201, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.
Follow-Up Questions
Who is the CEO of Cabaletta Bio Inc?
Dr. Steven Nichtberger is the Chief Executive Officer of Cabaletta Bio Inc, joining the firm since 2017.
What is the price performance of CABA stock?
The current price of CABA is $2.87, it has increased 1.96% in the last trading day.
What are the primary business themes or industries for Cabaletta Bio Inc?
Cabaletta Bio Inc belongs to Biotechnology industry and the sector is Health Care
What is Cabaletta Bio Inc market cap?
Cabaletta Bio Inc's current market cap is $263.0M
Is Cabaletta Bio Inc a buy, sell, or hold?
According to wall street analysts, 10 analysts have made analyst ratings for Cabaletta Bio Inc, including 6 strong buy, 8 buy, 3 hold, 0 sell, and 6 strong sell
